Panitumumab: A new frontier of target therapy for the treatment of metastatic colorectal cancer

Expert Review of Anticancer Therapy

Volumn 10, Issue 4, 2010, Pages 499-505

  Addeo, Raffaele ^a   Caraglia, Michele ^b   Cerbone, Domenico ^c   Frega, Nicola ^d   Cimmino, Gaetano ^e   Abbruzzese, Alberto ^b   Del Prete, Salvatore ^a  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Cardinale Ascalesi Hospital   (Italy)

^d Mauro Scarlato Hospital   (Italy)

^e Surgery Unit   (Italy)

Author keywords

EGF receptor; Human monoclonal antibody; KRAS; Metastatic colorectal cancer; Panitumumab; Target therapy

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; B RAF KINASE; BEVACIZUMAB; CETUXIMAB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; L 778123; MOTESANIB; OXALIPLATIN; PANITUMUMAB; SORAFENIB;

ACNE; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER MORTALITY; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; HEALTH CARE COST; HUMAN; HYPOMAGNESEMIA; METASTASIS; NAUSEA; NONHUMAN; ONCOGENE K RAS; PROTEIN TARGETING; RASH; REVIEW; SKIN DISEASE; SKIN TOXICITY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM METASTASIS; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 77951213494     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.28     Document Type: Review

References (40)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005). (Pubitemid 29094960)
2. Voldborg BR, Damstrup L, Spang- Thomsen M et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 8, 1197-1206 (1997). (Pubitemid 28164074)
3. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 21, 105-115 (2000). (Pubitemid 30114656)
4. Ranson M. Technology evaluation: ABX-EGF, Abgenix/Amgen. Curr. Opin. Mol. Ther. 5, 541-546 (2003).
5. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236-1243 (1999). (Pubitemid 29136253)
6. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203-212 (1990). (Pubitemid 20149352)
7. Caraglia M, Marra M, Meo G, Addeo SR, Tagliaferri P, Budillon A. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy. Recent Pat. Anticancer Drug Discov. 1(2), 209-222 (2006).
8. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy. Crit. Rev. Oncol. Hematol. 38, 17-23 (2001). (Pubitemid 32194591)
9. Adams R, Maughan T. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Rev. Anticancer Ther. 7, 503-518, (2007). (Pubitemid 46681806)
10. Esteller M, Gonzalez S, Risques RA et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J. Clin. Oncol. 19, 299-304 (2001). (Pubitemid 32112840)
11. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19(3), 508-515 (2008).
12. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
13. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091-2096 (2009).
14. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. (2010) (Epub ahead of print).
15. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712 (2008).
16. Mitchell EP, Perez-Soler R, Van Cutsem E et al. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology 21, 4-9 (2007).
17. Humblet Y, Peeters M, Siena S et al. Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab). American Society of Clinical Oncology, Chicago, IL, USA (2007) (Abstract 4038).
18. Michelini T, Hecht JR, Peeters M et al. Pooled analysis of five clinical trials examining the predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC). American Society of Health-System Pharmacists, Las Vegas, NV, USA (2007) (Abstract P141D).
19. Mancl EE, Kolesar JM, Vermeulen LC. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Am. J. Health Syst. Pharm. 66(23), 2105-2112 (2009).
20. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22, 3003-3015 (2004).
21. Weiner LMBA, Rowinsky E, Crawford J et al. Updated results from a dose and schedule study of panitumumab (ABX- EGF) monotherapy, in patients with advanced solid malignancies. Presented at: ASCO Annual Meeting Proceedings J. Clin. Oncol. 23, (2005) (Abstract 3059).
22. Hecht JR, Patnaik A, Berlin J et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110, 980-988 (2007). (Pubitemid 47312862)
23. Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007). (Pubitemid 46797944)
24. Van Cutsem E, Peeters M, Siena S et al. A Phase III randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): subset analyses in elderly pts and in pts with poor performance status. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA 19-21 January 2007.
25. Humblet Y, Peeters M, Siena S et al. Association of skin toxicity (ST) severity with clinical outcomes and health related quality of life (HRQoL) with panitunumab (Pmab). J. Clin. Oncol. 25, (2007) (Abstract 4038).
26. Mitchell EP, Hecht JR, Baranda J et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis. J. Clin. Oncol. 25, 408 (2007).
27. Hecht J, Posey J, Tchekmedyian S et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). Presented at: Gastrointestinal Cancers Symposium. San Francisco, CA, USA 26-28 January 2006.
28. Schwartzberg LS, Hurwitz H, Stephenson J et al. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). Presented at: ASCO Annual Meeting Proceedings. J. Clin. Oncol. 25, (2007) (Abstract 4081).
29. Peeters M, Van Cutsem E, Berlin J et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. Presented at: ASCO Annual Meeting Proceedings J. Clin. Oncol. 25, (2007) (Abstract 4138).
30. De Roock W , Piessevaux H , De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19(3), 508-515 (2008). (Pubitemid 351325672)
31. Wainberg Z, Hecht JR. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin. Biol. Ther. 6, 1229-1235 (2006). (Pubitemid 44714148)
32. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J. Clin. Oncol. 25, 4057-4065 (2007).
33. Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672-680 (2009).
34. Marshall JL. Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: synergy or antagonism? J. Oncol. 2009, 937305 (2009).
35. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor - targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 101, 1308-1324 (2009).
36. Karapetis CS, Khambata-Ford S, Jonker DJ et al. Kras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
37. García-Sáenz JA, Sastre J, Díaz-Rubio García E. Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. Clin. Transl. Oncol. 11(11), 737-747 (2009).
38. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer 120, 781-787 (2007). (Pubitemid 46175397)
39. Caraglia M, Tagliaferri P, Correale P et al. Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb. Cancer Immunol. Immunother. 37(3), 150-156 (1993). (Pubitemid 23208006)
40. Caraglia M, Pinto A, Correale P et al. 5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. Ann. Oncol. 5(3), 269-276